Shares of Avita Therapeutics (AVH.AU) plummeted 20.74% in Friday's trading session following the release of its first-quarter earnings report. The sharp decline came as the company's financial results fell short of analyst expectations, despite showing year-over-year improvements.
Avita Medical, the parent company of Avita Therapeutics, reported a narrower loss of $0.53 per diluted share for the quarter ended March 31, compared to a loss of $0.73 per share in the same period last year. However, this figure missed the analyst consensus of a $0.45 per share loss. Revenue for the quarter rose significantly to $18.5 million from $11.1 million a year earlier, representing a 66.7% increase. Yet, this too fell short of the $20.1 million forecast by analysts surveyed by Visible Alpha.
Despite the negative market reaction, Avita Medical maintained an optimistic outlook, reaffirming its full-year 2025 guidance. The company anticipates commercial revenue between $100 million and $106 million, projecting a robust 55% to 65% growth compared to the previous year. However, investors seemed to focus more on the earnings miss than the positive forward guidance, leading to the substantial sell-off in the stock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.